Podcasts about qualio

Today we're heading across the Atlantic to speak to Dr. James Field, CEO of London-based LabGenius Therapeutics.LabGenius has a really exciting mission. James and his team of 60 scientists and engineers believe in the powerful combination of human and artificial intelligence, and are pioneering an ML-driven protein engineering platform - EVA - that can design and execute experiments for the development of next-gen antibodies, including complex multispecifics.LabGenius has already raised over $75m in venture capital and built R&D deals with some major pharma and biotech players. After founding the company in 2012, James was named in Forbes' ‘30 Under 30' list for science and healthcare, and even won Innovator of the Year award from the UK's Biotech & Biological Sciences Research Council. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

We made a bonus episode of From Lab To Launch to mark a special occasion: the launch of Qualio's fourth annual life science quality trends report in March 2025.Our very own Kat and Clive dug into the report and its fascinating findings to see how life science quality teams are spending their time, what they're planning for 2025, and what headaches and frustrations they're looking to conquer this year.Join us and dive into our report - and read the full thing at reports.qualio.com!Note: the audio in this episode has been made using artificial intelligence Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

As more preventative approaches to health are set to take center stage, some diseases can't be prevented but can be managed more proactively. Blood-based biomarkers, such as p-tau217, hold great promise for earlier, more proactive detection and monitoring of diseases such as Alzheimer's, and it's here that Quanterix plays a critical role.Their Simoa digital health platform serves as the backbone for the majority of p-tau217 tests on the market today, reducing reliance on costly PET and CSF testing and streamlining the diagnostic journey for Alzheimer's disease.Mark has been a leader in the biotech space for over 2 decades, with a string of leadership roles before he joined Quanterix in 2014 and became their CSO in 2022.Mark joined Meg on From Lab To Launch to discuss the exciting predictive power of biomarker technology, and what the future holds for spotting and treating diseases early. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of From Lab to Launch by Qualio we interview Joseph Mossel, CEO and co-founder of Ibex Medical Analytics. Joseph shares his journey from computer science to leading a transformative AI-driven company in pathology. Founded in 2016, Ibex aims to provide accurate, timely, and personalized cancer diagnoses using AI technology. Joseph discusses the challenges and insights from deploying AI in clinical settings, the importance of partnerships, and the company's vision for the next few years. Tune in to learn how Ibex's innovations are reshaping cancer diagnostics and making a significant impact on patient outcomes.https://ibex-ai.com/ https://www.linkedin.com/in/yossimossel/ 00:00 Introduction to the Podcast00:26 Meet Joseph Mossel, CEO of Ibex01:14 The Founding and Vision of Ibex05:59 Ibex's AI Technology and Its Impact07:41 Challenges and Overcoming Them09:54 AI in Cancer Diagnostics15:12 Future of AI in Pathology17:15 Partnerships and Collaborations19:58 Advice for Labs and Entrepreneurs23:29 Ensuring AI Reliability and Quality25:48 Fun and Final Thoughts Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Earlier this year, Thermo Fisher Scientific opened its first clinical trial Innovation Lab in Center Valley, Pa., designed to foster a culture of collaboration by providing a dedicated space for industry partners to come together, share ideas and co-create solutions for the industry's biggest challenges. The global clinical trial market was valued at over $80 billion in 2023, and that's projected to grow by 6.5% every year until 2030. But alleviating innovation silos is the only way to move the clinical trial industry forward and tackle its current challenges. And it's here that Senior Director of Innovation & Program Management Sarah Englert's mission is focused...https://www.linkedin.com/in/sarah-blake-englert-70557421/https://www.thermofisher.com/us/en/home.html Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today we welcome Kerry Love, the co-founder of Massachusetts-based (and wonderfully named) Sunflower Therapeutics. Established in 2018, Sunflower is dedicated to advancing biologic medicines and enhancing global vaccine accessibility through cutting-edge protein manufacturing technologies.As a women-owned organization, Sunflower has a stellar team of scientists and engineers renowned for their expertise in perfusion fermentation, purification process development, biopharmaceutical manufacturing, and quality management. Their mission-driven approach revolves around simplifying bioproduction complexities with their modular, automated, and fully integrated platform. This transformative technology empowers innovators to swiftly manufacture critical biologic products precisely where they're needed most.https://www.linkedin.com/in/kerry-love-1a197811/ https://sunflowertx.com/  Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Carna Health is focused on applying technology to revolutionize kidney care by unlocking the early detection and management of chronic kidney disease (CKD). They provide clinical-grade software as medical devices that deliver instant health metrics, such as creatinine, eGFR, and uACR levels, from small patient samples. Their platform integrates with existing healthcare systems and electronic healthcare records, promoting proactive and patient-centric care underpinned by accurate, real-time patient data.CEO and co-founder Salvatore Viscomi, MD, joined Meg to talk about the Carna Health mission, where current kidney care is going wrong, and what the future holds for kidney patients.More about Dr. Viscomi:Dr. Viscomi is the CEO and co-founder of Carna Health, a Boston-based SaMD company focused on revolutionizing how chronic kidney disease is spotted and treated early.https://carna.health/ https://www.linkedin.com/in/salvatore-viscomi/ Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Dr. Jonathan Hill, VP of Science and Technology and co-founder of Wasatch Biolabs joins the podcast today to talk about the future of genetic testing technology. Dr. Hill shares his journey in genetics, starting from his undergraduate days to co-founding multiple biotech companies. They discuss the cutting-edge genomic and bioinformatic methods being developed at Wasatch Biolabs, including targeted DNA methylation sequencing and its significant implications for personalized medicine and early disease detection. Dr. Hill also elaborates on the integration of lab work and data analysis in genetic research, partnerships in diagnostic advancements, the role of AI in the future of genetic testing, and the importance of quality management in product development. Additionally, he speaks about the challenges faced in implementing these technologies and how they are being addressed. The conversation concludes with Dr. Hill's vision for the future of genetic testing and his approach to preparing students for the industry's evolving landscape.00:00 Introduction to the Episode00:25 Meet Dr. Jonathan Hill01:45 Dr. Hill's Journey in Genetics03:27 Understanding DNA Methylation Sequencing06:15 Applications in Personalized Medicine15:06 Challenges in Implementing Assays18:40 Future of Genetic Testing Technology23:14 Importance of Collaborations and Partnerships26:58 Fun and Personal Insights27:43 Conclusion and Contact InformationMore about Dr. Hill:Dr. Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs, a biotechnology company committed to transforming the field of diagnostics. The company delivers reliable laboratory services, offering transparent testing and accurate results for biotech firms, patients, and research institutions.https://www.wasatchbiolabs.com/ https://www.linkedin.com/in/jonathon-t-hill/  Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Join us with guest Dr. Rolland Carlson, CEO of Immunexpress to talk about the transformative work happening in sepsis diagnosis. Dr. Carlson discusses the importance of rapid sepsis diagnosis. The episode covers challenges faced during product development, regulatory achievements, and future plans for sepsis diagnostics. Dr. Carlson also shares advice on ensuring product quality and navigating FDA clearances.00:00 Introduction to From Lab to Launch00:25 Meet Dr. Rolland Carlson, CEO of Immunexpress01:31 Challenges and Innovations in Sepsis Diagnosis03:01 Impact of COVID-19 on Clinical Trials04:17 The Vision Behind Septicite Rapid05:17 Technical Insights into Sepsis Diagnosis14:00 Regulatory Achievements and Quality Management16:58 Integrating Septicite Rapid in Clinical Workflows24:00 Future Innovations in Sepsis Diagnostics25:34 A Personal Note from Dr. Carlson26:29 Conclusion and Farewellhttps://immunexpress.com/ https://www.linkedin.com/in/rollie-carlson-ph-d-059074a/  Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode we bring David Suhy, co-founder and Chief Scientific Officer at Earli back to the podcast. David shares the heartfelt founding story of Earli, the company's mission to make cancer a benign experience by catching it early, and their unique approach utilizing synthetic promoters for early cancer detection and treatment. He discusses challenges faced in clinical trials, the importance of quality and safety in research, and provides advice for other startups in life sciences. David also talks about the recent advancements at Earli, their funding journey, and offers valuable insights on navigating the dynamic field of scientific innovation. The episode concludes with a light-hearted discussion about David's passion for making pizzas in his backyard wood-fired oven.00:00 Introduction and Podcast Overview00:37 Guest Introduction: David Suhy from Earli01:19 The Founding Story of Earli04:24 Earli's Unique Approach to Cancer Detection06:33 Challenges and Innovations in Cancer Treatment10:06 Clinical Trials and Lessons Learned15:30 Funding and Financial Strategies18:56 Future Plans and Developments21:14 Quality and Safety in Research23:43 Advice for Entrepreneurs and Scientists25:27 Fun Facts and Closing Remarkshttps://www.earli.com https://www.linkedin.com/in/davidsuhy/  Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Todd Wilkens joined our host Melissa Perri on the latest episode of the Product Thinking podcast. Todd started his career in design and gradually transitioned into product development, now serving as the Chief Product Officer at Qualio. In this engaging episode, they discuss the importance of collaboration, shared goals, and breaking down disciplinary boundaries in organizations. Todd shares his extensive experience in various roles, including design and product development, and highlights the value of hiring smart people and giving them autonomy.

In this episode we are joined by Kelly Stanton, the Head of Quality Systems Improvement at Corden Pharma. Kelly discusses her transition back to the pharmaceutical industry after four years at Qualio, an eQMS provider. She also shares her improvement projects that make a real difference in her organization. Additionally, she shares insights on improving processes, the importance of regulatory compliance, and the impact of implementing changes within an organization. The conversation also delves into the benefits of using automated tools, making processes lean, and the significance of leveraging electronic tools to improve efficiency. Tune in to gain valuable insights into the pharmaceutical industry and the importance of continuous improvement in processes.

Join us in this inspiring episode of From Lab to Launch as we sit down with Marna Pacheco, the innovative founder of CapeAble Weighted Products. Marna turned a personal challenge into a pioneering enterprise that integrates fashion with function, providing therapeutic weighted products to those in need, from individuals with autism to medical patients across various settings.You'll learn:Marna shares her journey from designing a unique weighted cape for her daughter to founding CapeAble.Insight into the smartweight technology that sets CapeAble products apart in efficacy and style.Discussion on how CapeAble's products are making a significant impact in the medical field through non-pharmaceutical interventions.CapeAble's expansion into medical applications.https://www.capeable.com/Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

This episode of the From Lab to Launch podcast, brought to you by Qualio, features Dr. Sam Clark, CEO of Terran Biosciences. With a background in neurosciences from MIT and an MD and PhD from Columbia University, Dr. Clark shares his journey from academia to leading a pioneering company in neuropsychiatric therapeutics. He discusses the challenges and innovations in the development and supply of GMP psychedelic compounds, highlighting how these substances are making significant strides toward transforming mental health treatment. Dr. Clark also explores Terran Biosciences' approach to overcoming drug development hurdles, emphasizing quality management and patent strategies to ensure the delivery of affordable, effective treatments. His insights offer a glimpse into the future of psychedelics in mainstream medicine and the broader implications for treating various disorders beyond mental health.https://terranbiosciences.com/ Dr. Sam Clark's LinkedIn: https://www.linkedin.com/in/sam-clark-md-phd-133139199/ 00:00 Welcome to From Lab to Launch!00:40 Introducing Dr. Sam Clark and Terran Biosciences01:23 Dr. Clark's Journey: From Academia to Neuropsychiatric Therapeutics02:48 The Renaissance of Psychedelic Therapeutics04:36 Challenges and Innovations in Drug Development08:36 Quality Management at Terran Biosciences10:23 The Future of Psychedelics in Mainstream Medicine12:46 Expanding Beyond Neuropsychiatry: Terran's Broader Impact14:02 Navigating Innovation and Ethics in Patenting17:48 Advice for Aspiring Scientists and Innovators20:42 Dr. Clark's Personal Inspirations and Closing Thoughts22:21 How to Follow Dr. Clark and Terran Biosciences23:00 Wrapping Up and How to Engage with From Lab to LaunchQualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Listen in on our conversation with Rob Etherington, CEO of Clene Nanomedicine, a company pioneering nanotherapeutics for neurodegenerative diseases like ALS, multiple sclerosis, and Parkinson's. Rob discusses Clene's unique approach to improve mitochondrial function through a novel nanotherapeutic called CNM-au8, which has shown promising outcomes in clinical trials. He highlights the challenges in drug development, including funding and FDA approval processes, and underscores the importance of resilience, continuous learning, and strategic partnerships in advancing biotech innovations. The episode also touches on Rob's personal philosophy on leadership and the importance of women in leadership roles.https://clene.com/ https://www.linkedin.com/in/rob-etherington-431718/ Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode we interview Mark McDonough, the CEO of ChromaCode. The episode explores McDonough's journey to ChromaCode, from his early career as a naval officer to his roles at various medical and diagnostic companies. Under McDonough's leadership, ChromaCode has excelled in creating a high-definition PCR platform which enables fast, accurate, and affordable cancer diagnosis. The platform is particularly beneficial as it requires less patient tissue, provides rapid results, and has a lower cost than traditional diagnostic methods. McDonough also discusses the importance of partnerships in their go-to-market strategy and shared his insights on hiring and team development in today's competitive market. Looking ahead, ChromaCode expects to become a leader in developing innovative products for disease diagnosis, with a focus on patient-centered outcomes.https://www.chromacode.com/ https://www.linkedin.com/in/mark-mcdonough-b1055216/ 00:00 Introduction to the Podcast00:40 Meet the Guest: Mark McDonough, CEO of ChromaCode01:47 Mark's Journey to ChromaCode06:05 Insights on Leadership and Building High Performing Teams08:10 ChromaCode's Innovative Approach to PCR Testing10:36 ChromaCode's Contribution to Precision Medicine13:50 The Importance of Partnerships in ChromaCode's Strategy16:33 Future Prospects for ChromaCode18:27 Getting to Know Mark: Personal Interests19:13 Closing Remarks and Contact InformationAbout Mark McDonoughMark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of "From Lab to Launch" by Qualio, Meg welcomes Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience as a seasoned biochemical engineer, Ravi is a driving force behind Azzur's groundbreaking approach to lab spaces and cleanrooms.Discussion Highlights:Ravi delves into Azzur Group's evolution since its formation in 2010, emphasizing its roots in equipment and facilities for the biopharma industry. The conversation unfolds with a focus on Azzur's revolutionary "Cleanrooms on Demand" concept, drawing parallels to Legos for its flexibility and efficiency. Ravi explains the benefits of licensing lab space, offering a hybrid model that accelerates time-to-market for biotech and pharma companies.The conversation explores how Azzur ensures GMP compliance in multiproduct facilities, emphasizing quality systems and strict agreements. Ravi elaborates on Azzur's one-stop-shop approach, providing a range of services under one roof, from testing labs to consulting. The discussion touches on the lab space shortage, both pre- and post-COVID, and the potential implications for the industry.Ravi shares insights into emerging trends, expressing particular excitement for the potential decentralization of cell therapy manufacturing near hospitals. The episode concludes on a lighter note as Ravi reveals his personal interest in geography.Connect and Learn More:For those intrigued by Azzur Group's innovative solutions, virtual facility tours and more content can be found on their YouTube channel. Additionally, the Azzur website offers a wealth of information, including recent articles and client testimonials. Listeners are encouraged to explore further at Azzur Group's Website and YouTube Channel.This episode provides a comprehensive understanding of Azzur Group's transformative contributions to the biotech and pharma sectors, offering a glimpse into the future of flexible and efficient lab spaces.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this podcast episode, host Meg interviews Darwin Shurig, the founder and CEO of Shurig Solutions, Inc. (SSI), a talent management and executive recruiting firm. Darwin is a seasoned entrepreneur and talent management expert who has built a successful firm partnering with clients to fulfill their talent needs and strategically support initiatives. He also emphasizes the importance of hiring and retaining high-performing teams in life sciences.Episode Highlights:In the ever-evolving world of talent management, Darwin sheds light on the current trends and challenges associated with recruiting top talent, particularly in the medical device and pharmaceutical industries. He emphasizes the critical importance of leadership, mission alignment, and the right talent as key factors contributing to a company's success.Discussing the significance of retaining top talent, Darwin offers recommendations for organizations looking to keep their best employees. He stresses the importance of understanding a company's mission and creating a clear distinction between cultural fit and technical skills. He also highlights the need to focus on employee engagement, career growth opportunities, and providing a clear path for advancement.Darwin explains how he initiated various educational initiatives at SSI, such as the SSI Educational Webinar Series and the SSI Executive Conversations Podcast. These platforms serve as valuable resources for professionals in the life sciences industry, offering insights, knowledge, and opportunities to interact with industry experts.The conversation delves into the impact of COVID-19 on talent management and recruitment strategies. Darwin discusses how remote work, decision-making agility, and the cost of hiring have been affected. He emphasizes the increasing importance of autonomy for younger generations entering the workforce.Darwin emphasizes that attracting talent in the life sciences industry is always a challenging endeavor, with roles in clinical, regulatory affairs, scientific development, quality, and leadership positions being particularly demanding. He anticipates a growing need for commercial talent as well, driven by the burgeoning cell and gene therapy sector.Guest Speaker Bio:In this episode, we are joined by Darwin Shurig, the founder and CEO of Shurig Solutions, Inc. (SSI), a seasoned entrepreneur and talent management expert. Darwin has established a thriving executive recruiting firm that collaborates with clients to meet their crucial talent requirements, align strategic goals, and connect top performers with exceptional companies in the life sciences industry.Where to Learn More:To access more content from Darwin Shurig and SSI, you can visit their website at www.shurigsolutions.com. You can also tune in to the SSI Executive Conversations Podcast, available on various platforms including Spotify, Apple Podcasts, and their YouTube channel. For direct inquiries or contact, reach out to SSI at 317-983-HIRE or through their website.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Sepsis is often misdiagnosed, with approximately 40% of positive sepsis blood tests being incorrect. This leads to patients receiving unnecessary treatments, extended hospital stays, and risks associated with inaccurate diagnoses. In this episode, Greg Bullington CEO of Magnolia Medical Technologies discusses the mission and innovations of Magnolia Medical Technologies, which is focused on improving the accuracy of sepsis diagnosis and reducing the overuse of antibiotics.  Greg and his team have developed a technology to improve the accuracy of sepsis diagnosis and significantly reduce false positives.The conversation touches on the challenges of bringing innovations to market, the importance of building a quality culture within the organization, and the future of blood culture testing. Greg emphasizes the need for evidence and the delivery of lower costs and better outcomes to gain support in the healthcare industry. He also discusses the role of non-dilutive funding sources and collaborations with key opinion leaders to drive innovation.Magnolia Medical Technologies aims to continue solving the sepsis misdiagnosis problem and expand its reach. The company's vision includes developing additional solutions to improve diagnostic accuracy in various medical testing areas. Greg envisions a future with broader adoption of their technology, significantly reducing sepsis misdiagnosis and improving patient outcomes.Guest Speaker Bio:Greg Bullington is the co-founder and CEO of Magnolia Medical Technologies. Greg is an accomplished leader with a wide range of experience, having worked with senior executive teams in over 50 companies, ranging from Fortune 500 corporations to venture-backed startups. He's also an expert in intellectual property with numerous patents to his name. Greg's mission with Magnolia Medical Technologies is to eliminate the misdiagnosis of sepsis, a condition caused by blood infections and a leading cause of death, costs, and readmissions in hospitals nationwide.Where to Learn More:Website: Magnolia Medical TechnologiesLinkedIn: Company Profile and Greg Bullington's ProfileThis podcast episode provides valuable insights into the mission, innovations, and future goals of Magnolia Medical Technologies in the field of sepsis diagnosis. Listeners interested in healthcare innovation and improving patient outcomes will find this episode informative and engaging.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of "From Lab to Launch" by Qualio, host Meg welcomes Luca Yancopoulos, the CEO of Grapevine Technologies. Grapevine Technologies is a platform that revolutionizes the healthcare supply chain by connecting buyers with trusted wholesale suppliers, offering lower prices and a seamless online ordering process. Luca's passion for improving healthcare supply chain inefficiencies was sparked when he founded a medical supplies distribution company, Pandemic Relief Supply (PRS), during the COVID-19 pandemic, which delivered over $20 million in critical supplies.During the podcast, Luca discusses the impact of COVID-19 on healthcare supply chains, highlighting the outdated practices and inefficiencies in the industry. He explains how Grapevine Technologies aims to address these issues by providing a marketplace for medical practices and hospitals to connect with suppliers and optimize their supply chain.Luca also shares insights into the challenges and opportunities in the healthcare supply chain industry for 2024 and beyond, emphasizing the increasing demand for change and transparency.Listeners can find more information and updates on Grapevine Technologies by visiting their website (www.gograpevine.com) and following them on LinkedIn.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

20Angel is a series profiling European angel investors with the best Founder NPS. Episode 14 features Finn Murphy, angel investor & previously a Partner at Frontline Ventures, where he made 24 fund investments and 8 angel investments in his 4 and half year tenure. In that time, he has seen 3 companies through to exit with Workvivo selling to Zoom, Overwatch to Benchling and Modulz to WorkOS. He's also backed companies including Localyze, Conduktor, Unleash, Thursday and Qualio. Today's episode is a special one as Finn announces what he's been working on over the past year, exclusively for 20Angel. The format for 20Angel is consistent across show, with questions including: What are some of the non-obvious things they look for when investing in a company? How they work with their Founders? How Founders should approach them? What they think makes a great angel investor?

In this episode, you will learn how Lindsay Orem was able to bring to the table her rich experience, and her arsenal of vendors and speakers as the Foundational Events Manager in charge of full event strategies for Qualio.  Yanique had a down-to-earth conversation with Lindsay about planning an event on a tight budget, and how it is to be at the forefront of day-to-day marketing communications activities in the life science industry, creating impactful events from conferences, to conventions and summits.  And yes, you will also learn about Lindsay's life mantra and much more.  Highlights: 03:00 Lindsay's journey from working in the events and marketing industry to becoming the Foundational Events Manager in charge of full event strategies at Qualio.  03:39  What are some of the biggest challenges Lindsay faced in terms of managing events, and planning it from the ground up? 11:41  In terms of budget, what were the conversations and what are two ways that will convince the Finance department? 14:09  What are the first foundational steps Lindsay takes when it comes to building an event program? 16:03  Creating relationships with an arsenal of vendors and speakers is very vital in successful event programs. 18:20  What were some key elements you consider to ensure like its success and make a lasting impression on the attendees even with budget constraints? 23:42  How do you balance staying true to your brand and company culture while also experimenting with new ideas and concepts?  25:36  What does Lindsay do to ensure that events are inclusive and accessible for all the people who you want to attend? (...What does Lindsay think of feedback?) 30:53  Lindsay's favorite meant-to-be moments in her event planning career. 36:23  What is one event that Lindsay thinks all event professionals should attend, at least once in their career? 37:53  Closing CONNECT WITH LINDSAY OREM: Website LinkedIn CONNECT WITH YANIQUE DACOSTA: Website: ⁠⁠⁠⁠⁠⁠http://eventist365.com/⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠YKMD⁠⁠⁠⁠⁠⁠ Follow Us on Social Media: Host ⁠⁠⁠⁠⁠⁠@MissYaniDoesStuff /facebook⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠@YaniDoesStuff / Twitter⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠@yanidoesstuff / Instagram⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠YDaCosta / LinkedIn⁠⁠⁠⁠⁠⁠ Graphic Design Firm for Corporate Events ⁠⁠⁠⁠⁠⁠@TheYKMD / Facebook⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠@theYKMD / Twitter⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠@theykmd / Instagram⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠YKMD Visual Communication / LinkedIn⁠⁠⁠

On the podcast today we have David Schoneker who is currently the President of Black Diamond Regulatory Consulting, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries. The firm provides expert advice for difficult problems and training on excipient and food additive regulatory, quality and supply chain concerns. With over 45 years of experience working in these areas, Dave has developed strong networks with trade associations, regulatory agencies and pharmacopeias around the world. He is also an Adjunct Professor at Temple University's School of Pharmacy in their RA/QA Masters Program teaching courses in Global Excipient Regulations and the Regulation of Dietary Supplements. Prior to this, Dave was the Global Regulatory Director of  Strategic Relationships at Colorcon, Inc.Enjoy!Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today we have Dr. Jack Hoppin CEO of Ratio Therapeutics and Dr. John Babich Chief Science Officer of Ratio Therapeutics. The team at Ratio Therapeutics is developing a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. They just recently opened a 19,000-square-foot headquarters and R&D facility in Boston to continue their exciting innovation. We'll dive into how Ratio started, their growth, and what you can learn from their journey from Lab to Launch. Show notes:https://ratiotx.com/ Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Dr. Linnea Fletcher is a true pioneer at bridging biotech and education. On the show she explains how high school biotech incubators got started and how others can get involved. She also shares more about the upcoming innovATEBIO conference.  Dr. Fletcher she simultaneously joined the first National Science Foundation-funded National Biotechnology Education Center, Bio-Link, and received her first NSF-funded Advanced Technological Education grant to start Biotechnology high school programs in Texas. In 2015, she received an Emerging Technology Fund grant to build a Bioscience Incubator at ACC and several Wagner Peyser grants to equip it. Today, the incubator is full of start-up companies and students interning or working for these companies. About innovATEBIO www.innovATEBIO.org InnovATEBIO, the National Biotechnology Education Center funded by NSF (National Science Foundation). The center was funded 4 years ago at 7.5M for 5 years to coordinate over 134 two-year biotechnology programs and their educationalpartners for the purpose of creating a biotechnology workforce focusing on technician education. Every senior scientist needs 5 to 7 technicians for R&D, biomanufacturing and quality assurance and regulatory matters. (National Science Board report 2019). At the moment, there is not enough technicians being produced to meet the needs of the US biotechnology industry.About Dr. Fletcherhttps://innovatebio.org/iab-leadershipDr. Linnea Fletcher enjoys all forms of exercise but especially biking, hiking, and swimming. Her favorite pastimes are family events in the outdoors and travel. She received her Ph.D. in microbiology from the University of Texas at Austin, did two postdocs one at the Southwestern Medical Center and another in the Biochemistry Department at the University of Texas. She joined Austin Community College as a Department Chair in Biology and started the Biotechnology Program in 1999. At the same time, she joined the first NSF Funded National Biotechnology Education Center, Bio-Link and received her first NSF funded ATE grant to start Biotechnology high school programs in Texas. She worked as an NSF Program Officer from2008 to 2010 and was involved setting up the first Vision and Change Meeting. Once back on the job as Biotechnology Department Chair in 2015, she received an Emerging Technology Fund Grant to build a Bioscience Incubator at ACC and several additional grants to equip it. Today the incubator is full of startup companies and students interning or working for these companies. She was PI of the AC2 Bio-Link Regional Center, and is now the PI of InnovATEBIO, the NSF funded National Biotechnology Center. Combining economic development with educational opportunities is her passion. She is also PI and Co-PI on several other grants associated with the work of the center. Linnea Fletcher believes the best way to engage educate students is to involve them in industry projects from high school on –and show them that their education has a purpose and matters—involvement in startup companies does this!Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Dr. Carl Giordano joins us on From Lab To Launch!Carl is the co-founder and Chief Science Officer at Rebesana, a company dedicated to healthy aging and longevity. After years of studying science-backed research on health and aging, orthopedic spine surgeon Carl developed a proprietary supplement to target health on a molecular level.That supplement, backed by scientific publications, delivers a direct signal to cellular pathways in order to maintain health, longevity, and an athletic lifestyle as we age. The secret to slowing aging and extending our lives is closer than we think.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

We're welcoming a new host to From Lab to Launch! Kelly hands the baton over to Meg Sinclair. Listen in on their conversation about all things podcasting for life sciences, quality and transitioning over the podcast. A little about our new host. Meg has over 10 years of experience in Quality Assurance, Regulatory Affairs and Compliance across a range of industries - from non-profits to medical device start-ups.  Like many other Quality professionals who start out in another field or department, Meg found Quality after starting her career in Public Health, but her career path has always been about improving the lives of others which aligns with Qualio's vision.  Meg started with us in 2020 building out our own Quality System to achieve our ISO 9001 certification, followed by ISO 27001 certification in 2022.  Meg was also an instrumental part of the Qualio Plus program, where we provide the necessary procedures and advisory level guidance to our customers as they're coming onboard with Qualio.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Is psychological trauma really just in the mind? Research suggests it isn't.Today we're interviewing two innovators on the front lines of life sciences and co-authors of a recent book. Dr. Lipov has been called the “Einstein of modern anesthesiology” He's a renowned board-certified pain specialist and a huge proponent of the stellate ganglion block, a minimally invasive procedure that has been proven effective in treating PTSD symptoms. Jamie Mustard is an artist and a renowned strategic consultant. He is the author of the bestselling book “The Iconist: The Art and Science of Standing Out." Beginning as a child and then into adulthood he suffered years of trauma at varying levels before stumbling across Dr. Lipov and the Dual Sympathetic Reset Procedure or DSR. Today we're going to dive into their groundbreaking revelation that psychological trauma manifests as a physical injury that can be seen and monitored on a brain scan, and their revolutionary approach to resetting the sympathetic nervous system that has helped countless patients suffering from chronic pain, anxiety, PTSD, and other related conditions.THE INVISIBLE MACHINE: The Startling Truth About Trauma and the Scientific Breakthrough That Can Transform Your Life [April 11, 2023]Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today on the show we welcome Dr. Marcus Conant, chief medical officer of American Gene Technologies. Dr. Conant was one of the first physicians to treat AIDS in San Francisco while running the inpatient dermatology service at the University of California San Francisco. Before anyone recognized the virus or understood that it was about to become a global epidemic, Dr. Conant took the lead in forming the Kaposi's Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. He's dedicated much of his career to fighting for an end to HIV.Full bio Marcus A. Conant, MDChief Medical Officer at American Gene TechnologiesMarcus A. Conant, MD is a physician who treated thousands of HIV patients in the early 80s while running the inpatient dermatology service at the University of California San Francisco. Before anyone recognized the virus or understood that it was about to become a global epidemic, he took the lead in forming the Kaposi's Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. Marcus conducted early clinical trials, persevering despite seeing 94% of patients die during the epidemic's first years. His clinical experience sensitized him to the suffering caused by the disease. As a physician with a holistic perspective, his work expanded beyond the strictly clinical, to include education, research, and advocacy. Marcus is currently a clinical professor emeritus at the University of California Medical Center in San Francisco. He has published more than 70 articles on the treatment of AIDS, testified in front of Congress multiple times, and is a powerful advocate for the LGBTQ community.LinksMarcus Conant, MD, LinkedIn: https://www.linkedin.com/in/marcus-conant-056699229/American Gene Technologies Website: https://www.americangene.com/American Gene Technologies LinkedIn: https://www.linkedin.com/company/1127234/American Gene Technologies Facebook: https://www.facebook.com/amerigene/American Gene Technologies Twitter: https://twitter.com/americangeneAmerican Gene Technologies Instagram: https://www.instagram.com/americangenetechnologies/Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

There's no question that 2022 was a tumultuous year for biotech companies. As 2023 is underway, we're talking to Keith Woods, former COO and current strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on), a biotech company whose strong earnings come amid a downturn for the wider market and especially the biotech industry in 2022. While other companies continue to face challenges in this climate, this biotech is hitting its stride – argenx has managed rapid growth, and a successful drug launch.One major factor driving argenx's success: argenx's seasoned COO Keith Woods and his management philosophy of sustainable growth.https://www.argenx.com/ https://www.linkedin.com/in/keith-woods-5b8b67117/More about KeithKeith is was COO since 2018 and is currently a strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on). He comes with 25+ years of leadership experience in the biopharmaceutical industry, with the likes of Alexion, Roche, and Amgen. He has sage advice to offer about navigating market downturns, while still managing to grow and scale sustainably.**UPDATE** After recording this interview Keith transitioned from COO to Advisor on the argenx Board of Directors.  https://www.globenewswire.com/news-release/2023/03/02/2618906/0/en/argenx-Announces-Planned-Transition-of-Chief-Operating-Officer.html About argenxThe team at Argenx has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies. We'll get more into their discoveries, culture, and how our listeners can bring about innovation by focusing more and more on patients.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Chuck Rinker, CEO of PRSONAS, a self-proclaimed Human-AI Innovator, joins the podcast to discuss programming humanity into AI and revolutionizing the clinical trial industry through their iHealthAssist product. Chuck has gone from developing black-ops military tech and NASA/space-borne avionics through gaming to the creation of nuMedia Innovations and the patented technologies behind it including the Digital Personality Engine that brings human engagement to self-service solutions for airports, hospitals, and commercial markets. Listen how this applies to the healthcare and life science industries.https://www.prsonas.com/https://www.linkedin.com/in/chuckrinker/More about ChuckMy professional career has taken me from developing black-ops military tech and NASA/space-borne avionics through gaming, including directing the NCAA / Madden series of games for EA Sports. This lead to the creation of nuMedia Innovations and the patented technologies behind it. Our premier offering is the PRSONAS™ Digital Personality Engine bringing human engagement to self-service solutions for airports, hospitals, and commercial markets.About PRSONASSince inception, the team at PRSONAS have worked passionately to implement their vision of a digital workforce - empowering companies and organizations to automate the mundane, freeing time for human innovation. Leading international innovators such as Google for Entrepreneurs, Silicon Valley Open Doors, and FGNoviteiten Juryprijs have recognized us for our efforts.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today we're talking to Michael Tarselli Chief Scientific & Knowledge Officer of TetraScience. Mike was the Scientific Director for SLAS, a global professional society dedicated to lab automation and an Associate Director at Novartis building an external scientific collaboration platform. You can read the full bio in the show notes. TetraScience is bringing the future of scientific data to today and has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences and the delivery of life-saving therapeutics. More about Mike TarselliChief Scientific & Knowledge Officer of TetraScience, Mike Tarselli, explores the Tetra Scientific Data Cloud™ through knowledge capture, GxP compliance, and use case research. Previously, Mike was the Scientific Director for SLAS, a global professional society dedicated to lab automation and an Associate Director at Novartis building an external scientific collaboration platform. Mike received his Ph.D. from UNC Chapel Hill, completed postdoctoral work at Scripps Research, and his MBA through Quantic School of Business & Technology.Show Notes:Tetra Science Website - https://tetrascience.com/Demo of TetaScience - https://www.tetrascience.com/demoBenchmark Data from TetraScience  -https://go.tetrascience.com/researchreport_Scientific-Data-Imperative-Establishing-a-New-Benchmark-After-Two-Decades.htmlGXP Solution Brief - https://www.tetrascience.com/solution-brief/gxp-with-tetra-scientific-data-cloudQualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today we're talking to Mehdi Maghsoodnia, Co-founder of 1Health which is a personalized precision medicine powered by a lab testing platform that connects labs, clinicians and consumers. Listen to get more details about how 1Health is bringing diagnostic to the modern age. We love the mission of 1Health which is to bring advanced diagnostics to market faster and to make them more accessible, affordable and simple. Love that and it's similar to our mission at Qualio. About Mehdi MaghsoodniaMehdi is an industry fellow at UC Berkeley where he teaches innovation and entrepreneurship. He earned his Bachelor's at UC Berkeley and his MS from Stanford with an emphasis in AI and Machine learning. https://1health.io/https://www.linkedin.com/in/mmaghsoodnia/Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Kelly Stanton LinkedIn Qualio Website Project Medtech Website Duane Mancini LinkedIn Project Medtech LinkedIn

Dr. Brian Fengler joins us on the show to talk about the latest in healthtech and innovating EHR technology to save lives in fewer clicks. Brian is the Co-Founder and Chief Medical Officer of EvidenceCare (recently named as an Inc. 5000 Fastest-Growing Company), a company that provides a clinical decision support system (CDSS) that's uniquely integrated with the Electronic Health Record (EHR) to optimize clinician workflows.Dr. Fengler authored a treatment protocol for Pulmonary Embolisms when he was a resident at The University of Virginia. Despite being an expert in the field, he encountered a challenge while treating a 36-week pregnant patient suffering from a massive pulmonary embolism. Like 80% of healthcare decisions, he had to make a snap decision based on a quick internet search. Even though he was able to save both the mother and the unborn baby, he realized there was a gap in evidence-based information available to providers when they need it the most.Looking to fill the gap in 2014, Brian founded EvidenceCare with Co-Founder, Jim Jamieson, to create software that would help physicians make better decisions for their patients and hospital. Before EvidenceCare, he was an Assistant Professor of Emergency Medicine at St Thomas Midtown and Rutherford Hospitals, one of the Founding Physicians and Managing Partners of Physicians Urgent Care, and a partner-owner of the Middle Tennessee Emergency Partners physician group. Dr. Fengler is now revolutionizing decision support at the bedside by providing what clinicians need to give better, evidence-based care.Today, Brian shares more about his journey starting a healthcare tech company, EHR innovation, optimizing clinical workflows, and how the healthcare system can and should be improved.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

We're going to deviate from our typical life sciences for just a few moments just for fun to talk about dogs. We've heard about dogs using their olfactory system to detect biologic changes related to disease. Having a bit of a soft spot for dogs ourselves here at Qualio, when our friend Kayla Fratt reached out to be on the show, we thought it'd be fun to hear about her work in ecology and in the field doing conservation work.Kayla is the founder of K9 Conservationists and Journey Dog Training. She trains dogs to detect data for researchers, agencies, and NGOs. Along with the rest of the K9 Conservationists team, Kayla travels the world collecting data with her dogs and offering support to conservation detection dog programs. As a dog lover myself I'm thrilled to chat with Kayla today and how dogs are leaving their “paw prints” on the world. About KaylaKayla Fratt is the founder of K9 Conservationists and Journey Dog Training. With her nonprofit K9 Conservationists, Kayla trains dogs to detect data for researchers, agencies, and NGOs. Along with the rest of the K9 Conservationists team, Kayla travels the world collecting data with her dogs and offering support to conservation detection dog programs. Her other business, Journey Dog Training, provides the financial stability and freedom to pursue the nonprofit. Journey Dog Training offers free and low-cost behavior advice to owners struggling with their pet's behaviors.Show notes:k9conservationists.orgjourneydogtraining.comPatreon.com/k9-conservationistshttps://www.instagram.com/k9.conservationists/ https://www.facebook.com/k9conservationists https://twitter.com/kaylafratthttps://www.linkedin.com/in/kayla-fratt/ Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Today, we are chatting with Navid Alipour. Navid is the founder and CEO of AI Med Global. Navid believes that with consistent advancements in the healthcare industry, the best care is even more accessible than ever before. When treating cancer, Oncologists are attempting to match the best course of treatment to the individual but every cancer is as unique as the patient!His company, AI Med Global is making curated medicine accessible to cancer patients all over the world. By utilizing genetic information and a cleverly programmed AI, the technology behind CureMetrix and CureMatch are saving lives and improving healthcare. Listen in this chat with Navid to learn more about how advanced AI is allowing curated individualized treatments for cancer and other exciting progress in the AI and medical industry. More about Navid:Navid Alipour is the Chief Executive Officer at AI Med Global, a company focused on Artificial Intelligence Technology that improves healthcare and helps save lives. AI Med Global is a roll-up of two companies Navid cofounded, CureMetrix and CureMatch. He is also a founder of AI focused VC fund, Analytics Ventures. Through the founding of multiple Artificial Intelligence (AI) companies, Navid is a long-time entrepreneur in the AI space with an emphasis on the convergence of AI and the life sciences, which is also called Wellness Science. He seeks to identify scientists and domain experts in their respective fields to that are solving massive pain problems to take to market, by building companies from inception. While he is a VC and part of the founding of Analytics Ventures, he considers himself an entrepreneur at heart.Links:https://conquer-magazine.com/issues/2022/vol-8-no-4-august-2022/1895-precision-medicine-might-have-made-a-difference-for-my-mom-it-could-help-patients-with-cancer-todayhttps://academic.oup.com/jbi/advance-article-abstract/doi/10.1093/jbi/wbac046/6693780?login=falsehttps://www.linkedin.com/in/navid-alipour-a295777/https://aimedglobal.com/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Today we are chatting with Dr. Brandon McNaughton, CEO and Co-founder of Akadeum Life Sciences. Brandon is an award-winning inventor and scientist with over 15 years of experience working with magnetic beads and nanoparticles. His experience includes the development of new types of particles, separation, and biosensors. Brandon brings previous startup experience in the life sciences and venture capital. He is also a recognized expert in customer discovery and in using human-centered design for high technology applications. Before Akadeum, he served as entrepreneur in residence for Detroit Innovate, an early-stage venture fund facilitated by Invest Detroit. He also founded and served as chief technology officer of venture capital-backed startup Life Magnetics. He earned a Ph.D. in applied physics from the University of Michigan.About AkadeumAt Akadeum, we seek to improve human health by enabling better processes. Our platform technology is broadly applicable, but we are particularly focused on process improvements in the areas of cell therapy manufacturing, clinical diagnostics, and cell & molecular research.Akadeum is revolutionizing the way separations are performed, including cell separation, nucleic acid extraction, chemical separation, and so much more. The power of our platform is that we've developed an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to solve the problems of tomorrow.Links:https://www.akadeum.com/https://www.linkedin.com/in/bhmcnaughton/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Today, we are excited to chat with Jeff Galvin, CEO of American Gene Technologies®. We are so glad to have Jeff back on the show, we first spoke with him last March to learn about American Gene Technologies and what they were working on. I am excited to hear all the updates and accomplishments since we last chatted. Jeff is the CEO and founder of American Gene Technologies® (AGT).He earned his BA degree in Economics from Harvard and has more than 30 years of business and entrepreneurial experience including founder or executive positions at various Silicon Valley startups. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH and the incredible projects he was working on in gene and cell therapy. Jeff has contagious energy for gene technology and the future of curing for the incurable like HIV, cancer, and PKU. Links:www.americangene.comhttps://www.linkedin.com/in/jeff-galvin-60258/https://www.americangene.com/news-releases/agt-hiv-trial-enters-phase-withdrawing-antiretrovirals/ https://www.americangene.com/milestones/hiv-cure-countdown/ Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Cork native Robert Fenton's decision to move his Dublin tech start-up Qualio to San Francisco was pivotal in the company's acceleration and more than 260% year-on-year revenue growth. Backed to the tune of $50m by Tiger Global, Fenton reflects on how the company has grown to 300 customers across the globe, spanning the medical device, pharmaceutical and biotech industries. 

Are you a life sciences start-up founder and want to bring your business to market, but don't know how? Marketing is something that is ever-evolving but should be part of every business' strategy.  In today's episode, you will dive into marketing strategies, testing, industry regulations, and more in the healthcare sector with Jason and Scott from Webtek Interactive. Webtek Interactive is a full-service marketing agency that works with enterprise clients. They specialize in digital strategy for companies in the Healthcare and wellness space. About Justin Justin's background is in marketing online businesses and technical sciences. He's consulted with over 300 businesses worldwide and worked in-house for companies like CHG Healthcare Services and Skullcandy.About Scott Scott is an entrepreneurial Kiwi with 20 years of experience in organic search marketing. Beyond partnering with healthcare companies, Scott's interest in the life sciences extends into biohacking and life extension.About WebtekSuccessful marketing in today's ever-changing, online landscape requires multidisciplinary skill,  proven strategy, and perfectly executed development. Luckily, we've got the team and the tools for the job. (In fact, this is kind of our whole deal.) We're a full-service digital marketing agency with offices in Salt Lake City, UT, and Austin, TX. Your goals are our goals, and with our decades of expertise, we'll help you meet them. We handle the complicated stuff—all you have to focus on is minding your business (we'll mind it,  too). LinksWebtek Interactive: https://webtek.co/Justin Crawmer | LinkedIn: https://www.linkedin.com/in/justincrawmer/Scott Miscall | LinkedIn: https://www.linkedin.com/in/scottmiscall/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

We all experienced the importance of at-home testing from the Covid19 pandemic and today's guest is helping bring rapid, affordable, and accurate tests to everyone including traditionally underserved areas.  Dive into how Domus Diagnostics got started, the importance of Nucleic Acid Testing, and getting started with clinical trials to get FDA clearance with Kelly and Paul on this episode of From Lab to Launch.About Paul ChapmanFrom sales representative to CEO, Board Member and Angel Investor, Paul Chapman has over 25 years of international business leadership experience in Molecular Diagnostics, Point of Care Diagnostics, Medical Devices and Life Sciences. He is skilled at change agent and is a creative, action-oriented leader with a broad base of international Diagnostic, Medical Device and Life Sciences executive experience.  Whether creating a new business or optimizing existing business models, Paul has created significant value by focusing on development of a high-performance culture through professional "A+" teams that he helps build.About Domus DiagnosticsDomus Diagnostics  seeks to create tests for infectious diseases that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises. All this not only in the US but in every global market including underserved areas - talk about a big vision! LinksDomus Diagnostics: https://www.domusdx.com/ Paul's LinkedIn:  https://www.linkedin.com/in/paul-chapman-7b44508/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez 

Today on the show we're joined by Shuo Qiao, Co-founder and Chief Technology Officer of Moving Analytics. We discuss his career path and how it earned him a spot on the Forbes 30 Under 30 list, his interest in computer science, and crossing paths with his future business partner. Dive into funding strategies, the rise and global impact of telehealth, and the future of digital health tech on this episode of From Lab to Launch. About Shuo QiaoShuo Qiao is the Co-founder and Chief Technology Officer of Moving Analytics. Shuo earned his bachelor's degree in computer science degree from Beijing Jiaotong University and the top engineering university in India, the Indian Institute of Technology Madras. In 2013, he moved to the US to pursue his master's degree in computer science from the University of Southern California. He's now the Co-founder and Chief Technology Officer of Moving Analytics, a digital health company that reduces the chance of a heart attack through digital cardiovascular disease prevention programs.About Moving AnalyticsMoving Analytics is a digital health company with the mission to conquer cardiovascular disease as the leading cause of death by empowering people with tools to adopt healthy lifestyles. They work with a multidisciplinary team of cardiologists, nurses, nutritionists, and exercise physiologists to create personalized rehab programs for heart attack patients which they can access anywhere through their mobile phones. LinksShuo Qiao | LinkedIn:https://www.linkedin.com/in/shuo-qiao-0b813452/Moving Analytics: https://www.movinganalytics.com/ Forbes 30 Under 30: https://www.forbes.com/30-under-30/2018/healthcare/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez 

Host Dr. Nick van Terheyden, aka Dr. Nick, discusses Quality and Speed for Healthcare Life Sciences with Robert Fenton, CEO & Founder of Qualio. Their discussion includes moving quickly and safely in Pharma and BioTech, quality management solutions and software to meet complex regulatory compliance requirements without sacrificing speed to market. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Today we're catching up with Dr. Heather Underwood, CEO of EvoEndo. EvoEndo recently completed an $8.4 million Series A financing round on the heels of 510(k) FDA clearance in early 2022. We first spoke with Dr. Underwood in June of 2021. In this episode, we chart a course through her accomplishments, lessons learned through the FDA clearance process, working with CROs, and hear firsthand about the challenges she's tackled as Chief Executive of a medical device startup ready to revolutionize clinical endoscopy practice with a safer, faster, cost-effective alternative. About EvoEndoEvoEndo, founded in 2017 by Dr. Joel Friedlander (Chief Medical Officer), is making unsedated transnasal endoscopy a reality. General anesthesia has been the standard of care for pediatric patients undergoing endoscopies. This can be a traumatic experience, especially for patients with chronic health conditions who may require the procedure several times a year. But EvoEndo's single-use small-diameter device for unsedated transnasal endoscopy is ready to transform this medical necessity. The company received 510(K) clearance from the FDA in February of 2022 and is poised for a commercial launch of its innovative product. About Dr. Heather UnderwoodDr. Heather Underwood joined EvoEndo as CEO in 2019 after completing the Stanford Biodesign Innovation Fellowship for medical devices. Dr. Underwood completed her Ph.D. at the University of Colorado Boulder's ATLAS program where she developed and implemented clinical decision support systems for midwives and nurses in Kenya, receiving the NSF Graduate Research Fellowship grant and a Gates Grand Challenges grant to support her research. She has spent the last 10 years founding and leading medical device startups, non-profit life science organizations, and innovative academic initiatives. LinksHeather Underwood | LinkedIn:https://www.linkedin.com/in/hmunderwood/ EvoEndo:https://evoendo.com/Titan100:https://www.titan100.biz/2022coloradotitan100Proxima CRO:https://www.proximacro.com/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez 

Our guest: Rob Fenton, Founder & CEO at QualioIn this episode, we discussed: Predictions for 2022 API's for data sharing Trends in healthcare   The shift to remote work in healthcare. This episode was recorded in January 2022. Our sponsors for this episode are BlocHealth, Curation Health, ChenMed & MediTelecare.BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to www.blochealth.com follow BlocHealth on social media - @blochealth"Curation Health's advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com & follow Curation Health on social media - @curationhealth"ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. For more information, please go to www.chenmed.com & follow ChenMed on social media - @chenmed"MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology." For more information, please go to www.meditelecare.com & follow MediTelecare on social media – @meditelecareTo learn more about Qualio please use the links below:- Website - LinkedInAlso, be sure to follow Slice of Healthcare on our social channels:- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world's most successful medtech founders and executives. If you're interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.

Today's guest is Ian Chan the co-founder and executive chairman of Abpro. Abpro is improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian explains how their technology is "future proofing" antibodies. Recently, Abpro announced its ABP 310 COVID antibody retains neutralization activity against the SARS-CoV-2 Omicron variant, which is exciting. You'll hear the full story coming up but first some quick takeaways you'll get from today's conversation:How Abpro is cutting the time to generate antibodies for testing from 1 year to 2 months. What all founders should focus on to facilitate fundraising - what Ian calls “first-class science”Unique challenges a company faces when it's in high-growth mode and how to prepare. More about Ian he co-founded Abpro with his brother, Dr. Eugene Chan, who is the CEO. Not everyone goes into business with family but they've done it successfully a few times actually. Ian received an AB from Brown University and MBA from Harvard University. Show notes:https://abpro.com/Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron VariantQualioApply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Qualio's eQMS is a quality management system for pharma, devices, and cannabis is built on the 12 pillars of quality,

Host Matt Fisher's guest is Robert Fenton, CEO, Qualio. The discussion topics include, impact of quality on life sciences development cycle, challenges created by data collection obligations, driving the build of good business not business for compliance; technology life cycle and power of new tools, COVID lessons of ability to move quickly. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

This past year—much like the year before—has put increasing pressure on professionals working in life sciences and healthcare. We hear the inspiring and sobering stories from those on the front lines of life sciences who are making a real difference to save lives. To celebrate the strong tailwinds behind us and the people who helped pave this road to success – notably amid an ongoing pandemic – Qualio is donating for the 2nd year in a row 1% of annual revenue. We call this initiative 1% For All Life. Every year we will continue to support organizations that ensure underserved communities receive the healthcare they need.At Qualio, we share a core belief that everyone deserves to live a long, happy and healthy life. We are continuing our work to extend this mission by supporting organizations that align with our shared values. After nearly two years in a global pandemic, we feel strongly that we must continue to support better healthcare access to underserved communities. Here is where our donations will go as 2021 comes to an end:Saint Francis Foundation: Community Crisis Response Fund (COVID-19)Gates Philanthropy Partners: the Must-Solve Problems fund with the hope of supporting their efforts to drive healthcare innovation, eradicate disease, and reduce inequity in the world.Learn more about why we've made this pledge and hear from Saint Francis Foundation's President, Mark Ryle on their inspiring work in this episode of the From Lab to Launch podcast.Links:https://www.saintfrancisfoundation.org/https://sfcommunityhealth.org/program/hhome/Find service opportunities near you: https://www.volunteermatch.org1% for All Life 2020 articleApply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

You may have heard the adage, "an ounce of prevention is worth a pound of cure." Today's guest Joseph Mocanu, PhD shares how companies and entrepreneurs across the world are overcoming barriers to bring an ounce of prevention to emerging markets and rural communities. His company, Verge HealthTech Fund focuses on seed stage healthcare technology companies relevant to emerging markets. He explains how each of us can get involved and be part of the solution to bridge the gap in life sciences between human capital and healthcare access. We each can make a difference.  Joseph Mocanu is the Founder of Verge HealthTech Fund. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 23 healthcare technology companies to date. Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.Show notes:Verge HealthTech Fund: https://www.vergehc.com/Joseph on LinkedIn: https://www.linkedin.com/in/jmocanu/Other podcasts from Joseph: https://www.podfol.io/profile/joseph-mocanu/Qualio: qualio.comMusic by keldez

Early in a startup's life, founders are the ones selling and finding those critical early customers. As the startup scales, this responsibility often transitions to a sales team. The transition is a vital moment in the company's journey, and mistakes can set the organization back years. In this episode, we speak to Josh Leslie, who has decades of sales and leadership experience spanning companies like VMware, Coraid, and Cumulus Networks. We explore the intricacies of building and scaling a sales organization and what are some of the pitfalls for founders. This is the last episode of our first season! Thanks so much to all our guests so far - and everyone who tuned in. We are looking forward to coming back in 2022. Make sure also to follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

The engineering function has rapidly evolved over the last few years. Rapid growth in the tech sector and the introduction of new technologies have forced engineering teams to innovate faster, be more agile and adept at cross-functional collaboration than ever before. In this episode, we talk about how engineering leaders can rise up to these challenges and more with Srini Kakkera. Srini is the head of engineering, AI/ML & Analytics at Marketo/Adobe, and previously held senior engineering leadership roles at organizations like SAP, Accela, and AlertEnterprise. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

Healthcare can be an incredibly challenging industry to navigate for startup founders. Complex decision-making processes, numerous stakeholders, long sales cycles make it very hard for startups to enter the market. This is where the ability to utilize partnerships with bigger players in the industry can be extremely valuable. Lisa Maki, a serial entrepreneur currently managing strategic partnerships for health and life science at Microsoft, has had a long and distinguished career in healthcare. Listen to our latest interview to get insights on how to navigate the industry. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

Episode Outline[01:21] Rich's background[03:35] Lessons and strategies[05:34] Approaching conversations and measuring success[08:54] Grain[11:44] Testing and hiring[12:46] Interesting and new things that Rich wants to tinker with[16:53] Know your fundamentals[21:21] Rich's influential peopleRich's InspirationsJeff WissZack UrlockerRich's brothersConnect with RichLinkedInWebsite

The role of a Chief Marketing Officer (CMO) has evolved tremendously over the years. What was once about building the brand and advertising has grown to include technology, analytics, and impact. Additionally, marketing works more closely with sales and customer success than ever before to ultimately bring a unified vision and value to customers. Amit Pande, global head of product marketing at Wrike, explores this evolution and draws upon his experiences at companies like Aviso, Tact, and HP, to build a roadmap for a successful marketing organization. Wrike, recently acquired by Citrix, is the most versatile work management platform for enterprises. Over 20,000 customers, including Airbnb, Apple, Walmart, Estée Lauder, Oracle, and Tiffany & Co., and 2M+ users across 140 countries depend on Wrike to help teams plan, manage, and complete work at scale. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

Chief Revenue Officer is a wide-reaching and highly strategic role within a business, spanning sales, marketing, customer success, etc. Christof Baumgartner, former CRO at MobileIron, went through a unique journey with the company, from its startup days all the way to an IPO and ultimately acquisition. In the latest episode of the Enterprise Leaders podcast, Arun Penmetsa, partner at Storm Ventures, talks to Christof about what the “day in the life” of a CRO looks like - and how to scale to 15,000 customers and beyond. MobileIron helps companies worldwide enable their employees to choose the best devices and the best apps they want to do their work. MobileIron has over 17,000 customers worldwide. The company was founded in 2007 and backed by top-tier investors, including Sequoia Capital, Norwest Venture Partners, and Storm Ventures. MobileIron conducted a successful IPO in 2014 (NASDAQ: MOBL). MobileIron was acquired by Ivanti for $872m on December 1, 2020. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

In the next episode of Enterprise Leaders, we explore the role of the engineering team. Arun Penmetsa, a partner at Storm Ventures, is joined by Vahed Qazvinian, co-founder and CTO at Praisidio. Drawing on his experience as a CTO and an engineer at companies ranging from startups to multinational organizations like Google, Vahed talks about how the engineering team can be a true partner to the rest of the organization and how to develop an engineering-driven culture within the company, and much more. Praisidio is a venture capital-backed Enterprise Risk Management AI software company. Founded in 2019 and headquartered in Silicon Valley, their patent-pending product Procaire is the first of its kind Talent Risk Management platform which provides early employee attrition risk detection, assessment, prioritization, explanations, and action workflows to materially improve retention and employee work life. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

In this episode, we do a deep dive into the product role within a company - one of the most vital functions for any business. Arun Penmetsa, partner at Storm Ventures, interviews Charanya (CK) Kannan, chief product & engineering officer at TalkDesk. CK shares the lessons from her journey to where she is today - leading a team of more than 850 employees. Talkdesk is a global “unicorn”, providing a better way for businesses and customers to engage with one another through its cloud contact center solution. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

In the 2nd episode of the “Enterprise Leaders” podcast, Arun Penmetsa, partner at Storm Ventures, interviews Mahesh Baxi, co-founder & CEO of Provus. Drawing on his vast experience at companies like Apttus and MyAlly, Mahesh shares insights on building a successful customer success function at your company - and how to become an effective CS leader. Provus (https://www.provusinc.com/) provides a revolutionary CPQ services solution that finally solves the age-old legacy problem of excessively long quoting and deal construction processes. Customers can accelerate turnaround time, grow deal sizes, and increase win probability faster – all while improving their gross margin and mitigating compliance risk - with AI-driven what-if scenarios, real-time collaboration, flexible approval workflows, automated SOW generation and more. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1 billion in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo (IPO/Vista), MobileIron (IPO/Ivanti), Pipedrive (Vista), Qualio, SalesLoft, Splashtop, Talkdesk, Tekion, and Workato. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

Our guest: Robert Fenton, Founder & CEO at Qualio. "Qualio takes the pain out of quality management and regulatory compliance for the entire Life Sciences ecosystem." In this episode, we discussed: - His background - Qualio's why-how-what - Recent Series B funding announcement - Why their quality management technology is more important than ever for life sciences companies? - How he sees quality management for life sciences further evolving? - ...and much more! Our sponsors for this episode are BlocHealth, Curation Health, ChenMed & MediTelecare. BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to www.blochealth.com and be sure to follow BlocHealth on social media - @blochealth "Curation Health's advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com and be sure to follow Curation Health on social media - @curationhealth "ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. Operating over 50 medical centers in eight states, we are known to our patients as Dedicated Senior Medical Center, Chen Senior Medical Center, or JenCare Senior Medical Center." For more information, please go to www.chenmed.com and be sure to follow ChenMed on social media - @chenmed "MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology. For more information", please go to www.meditelecare.com and be sure to follow Meditelecare on social media – @meditelecare To learn more about Qualio please use the links below: - Website - LinkedIn - Facebook - Twitter Also, be sure to follow Slice of Healthcare on our social channels: - Website - Facebook - LinkedIn - Twitter - YouTube - Instagram - Newsletter

Rich Taylor the VP of Marketing of Qualio shares how to a growth plan. Get more info at https://www.qualio.com/

Welcome to the inaugural episode of the “Enterprise Leaders” podcast! In this one Arun Penmetsa, partner at Storm Ventures, interviews Travis McPeak, head of product security at Databricks. Drawing on his illustrious career across companies like Netflix, IBM and Symantec, Travis shares his unique tips on breaking into the security industry and becoming successful. Built on a modern Lakehouse architecture in the cloud, Databricks combines the best of data warehouses and data lakes to offer an open and unified platform for data and AI. More than five thousand organizations worldwide — including Shell, Comcast, CVS Health, HSBC, T-Mobile and Regeneron — rely on Databricks. About Storm Ventures Storm Ventures is a Silicon Valley-based venture capital firm that is focused on building enterprise leaders with over $1B in capital under management. Over its 20 year history, Storm has partnered with entrepreneurs on the startup journey to address some of the most challenging problems that businesses face across the B2B enterprise software space. Portfolio companies include Algolia, Marketo/IPO, MobileIron/IPO, Pipedrive, Qualio, Salesloft, Splashtop, Talkdesk, Tekion, and Workato. Make sure to also follow us on Twitter (https://twitter.com/stormventures) and check out our website (www.stormventures.com/thoughts) for a lot more content on building & scaling successful B2B SaaS businesses. --- Send in a voice message: https://podcasters.spotify.com/pod/show/enterprise-leaders/message

This month, $150m was raised by Peter Foley's LetsGetChecked, giving the five year old startup a valuation of over $1bn. Last month, €100m was raised by two Irish startups — Wayfarer (€62m) and Qualio (€41m). The month before that it was a handful of others, such as Payslip. It means that well over €1bn will be raised year, significantly up on last year. What's going on with these eye-watering sums? Is there any suspicion that we may be in a frothy boom at the moment? Is tech just benefitting from a lack of other places to put your money? Or has there been a transformation in the underlying value of Irish tech companies? Adrian is joined by seasoned venture capitalist (CEO of Scale Ireland) Brian Caulfield and the Irish Independent's deputy business editor, Jon Ihle.

It only takes one ground-breaking MedTech startup to change a product category forever. Back in 2006, serial entrepreneur Steve Kelly partnered with MIT researchers to take an anti-bleeding gel product to market. The biodegradable gel was a significantly better option for many hemostat applications, compared to alternatives like bandages, surgical clamps, tissue adhesives, vasoconstrictors, and cauterization. Today, topical hemostatic agents are considered the most efficient, effective, and safe option to stop bleeding in many patients and conditions.Winning medical device startups have a few factors in common, according to McKinsey research. First, they all have an idea that can provide consistently superior experiences to all users, including patients, caregivers, and clinicians. They will also “reimagine processes to dramatically reduce costs and accelerate decision making.” The most successful MedTech companies manage to get closer to the patient by providing an innovation that's better, cheaper, safer, more convenient, or somehow just a better option.In order to get close to the patient, MedTech startups need to achieve velocity in the early stages to provide proof-of-concept, secure funding, and demonstrate clinical safety for regulatory approval. There's no room for mistakes or delays in a hyper-competitive market space. A strong baseline of compliance is crucial from day one to ensure there are no barriers to obtaining FDA approval or a CE Mark.That's one of the reasons we exist. Qualio is quality management software for the life sciences ecosystem. ABLE HUMAN MOTIONDAY ZERO DIAGNOSTICSGARWOOD MEDICAL DEVICESX-COR THERAPEUTICSFLATIRON HEALTHIf you can think of any other innovative companies that we should feature on from lab to launch, Let us know by filling out this form:https://docs.google.com/forms/d/e/1FAIpQLSeEU7Owi8VDv30hzmWbj4JsXPKyfsWvKXHMeghEAyirAbR18A/viewformSee interviews and episodes on https://www.qualio.com/from-lab-to-launch-podcast.Music by keldez

Today, we're introducing a new type of episode called Quality Quick Tips.  Periodically we'll focus on specific aspects of quality management since we love to nerd out on all things quality and compliance. Call us weird. Call us what you want, but quality management is what we love to do. And we do it well ...so why not have some fun along the way! Today, two of Qualio's QA experts, Kelly and Ezra talk about how to maintain and improve your quality management while working remotely. It was a conversation that they had in the midst of the COVID 19 pandemic, but it still applies today.  As many organizations are still adjusting to a new normal of remote quality work, they cover important aspects like what questions to ask to better evaluate and prioritize tasks, the what and how to communicate about quality issues, how to manage remote audits, the importance of documentation all of these changes that are happening. Internal and external factors and a lot more. Building and improving a culture of quality at your company can be done either remote or in person, and this episode can help you show how that's done. Music by: keldez

For the first time in healthcare, human ambition and technology are starting to intersect and AI is one of the main drivers. Listen in on this episode with Sam Dribin to learn about how AI is evolving to improve healthcare results.  Sam Dribin is the Chief Technology Officer for CureMetrix, an AI company focused on solutions that support radiology.Sam has a diverse background in technology including Biotech software development with expertise in the technical issues facing healthcare and life science companies and laboratories.For the last five years, he's been on the forefront evolving artificial intelligence with solutions that are focused on AI-based mammography to improve cancer detection. We've known Sam and CureMetrix for some time as a customer of Qualio, but today he shares his insight into how AI can impact healthcare such as reducing false-positives and increasing access to healthcare everywhere.Show notes: https://curemetrix.com/Sam Dribin's LinkedInRadiology Society of North AmericaMusic:keldez

Listen to this chat between Qualio CEO, Robert Fenton and Claire Bonaci from Microsoft about how the life science industry is evolving.  We cover a wide of topics and trends based on her expertise and how she aspires to inspire young women interested in STEM and leadership roles. Guest Bio:Claire currently serves as Sr. Director of the Pharma sub vertical of the US Health & Life Sciences department at Microsoft. She works in partnership with US life science companies, pharma, and health organizations to create innovative Microsoft solutions specific to the company's issues affecting their patients and their business.She brings with her an expertise in the clinical trial and pharmaceutical industry, having been a global study lead on oncology clinical trials at a large pharmaceutical company prior to joining Microsoft. She has deep understanding of the clinical trial value chain and the complex nuances that biotechnology and life science companies experience. She is passionate about the many services and innovations Microsoft has to offer to reduce time to market for new drugs and provide better outcomes to patients.Claire is also the producer and host of the Confessions of Health Geeks podcast, an industry focused podcast on the biggest trends and pain points in health and life sciences. Claire also has a passion for inspiring young women to be interested in STEM and leadership roles in STEM related fields. Show notes: https://healthpodcastnetwork.com/show/confessions-of-health-geeks/https://www.linkedin.com/in/clairebonaci/https://entrepreneur.m12.vc/submithttps://steveblank.com/2013/08/20/reinventing-life-science-startups-medical-devices-and-digital-health/ Music by keldez

2020 has been an unprecedented year. In times like these, mission-driven companies should challenge themselves to stay focused on their immediate goals while not losing sight of their bigger vision. In an effort to reinforce our mission and demonstrate our values, Qualio is committing to what we call 1% For All Life. Starting this year, Qualio will donate 1% of our annual revenue to improving healthcare access for vulnerable populations.Qualio's mission is to enable organizations to launch and scale life-saving products. While this supports our core belief that everyone deserves to live a long, happy, and healthy life, we are now expanding our mission by supporting organizations that ensure underserved communities receive the healthcare they need. Increasing the quantity and quality of treatment options does little to help those who cannot easily access the existing healthcare system. I saw this first hand while working as a pharmacist in large urban centers, rural communities, and drug addiction services in Ireland's largest prison. It became clear to me that the ability to access quality healthcare has an enormous impact on people's lives, and that we all have an opportunity to make a difference here.After months of living through a global pandemic, we feel privileged to be able to give something to those that need better healthcare access. Here is where our donations will go in 2020:40% to the Bill & Melinda Gates Foundation, Combating COVID-19 Fund40% to the Saint Francis Foundation20% to Qualio Team Member choice (each Qualio team member is given an amount to donate to a cause of their choosing)To all our wonderful teammates, customers, and partners - thank you from the bottom of our heart for making all of this possible.Show notes:https://www.saintfrancisfoundation.org/See more information about From Lab to Launch by QualioMusic by keldez

Welcome to the From Lab to Launch podcast by Qualio. Discover inspiring stories from those on the front lines of life sciences. You'll hear founders share their insights from launching and scaling their business, investors giving their outlook on funding, industry experts unfolding their latest insights and research, and quality professionals offering advice to navigate the regulatory maze and avoid audit pitfalls.Episodes are about 30 minutes and published each week on all major podcast players. Tune in and leave inspired to bring your life saving products to the world.If you want to be a guest on the show, fill out this brief application: https://forms.gle/Yp7uKnSXTCPtTdRcA.Music credit:Keldez

“March 12, 2020 was the day that the Dow Jones Industrial Average had its largest drop since 1987, the year I was born. That was the day I decided to take the next step and start fundraising for our Series A.” But how on earth did Corkman Robert Fenton, founder of life science data management firm Qualio, do it? This week, he gives Adrian the story of how he went from zero to $11m, from multiple VC firms, in 90 days. He also talks about the temptation that some companies now have to leave San Francisco, where he now lives.